CD9 and acute lymphoblastic leukemia: Previously, Nishida et al performed a comprehensive analysis of surface markers on several B-ALL cell lines and identified that CD9 is a useful positive-selection marker for the identification of CSCs in human B-acute lymphoblastic leukemia and may also serve as a novel therapeutic target in this disease (59).